Marc Shenouda, CEO and Co-Founder of Neuropeutics Inc., gives insights into targeted therapeutics for neurodegenerative disease, winning the AbbVie Biotech Innovator’s Award, and earlier detection for ALS.

Dr. Bettina Hamelin, President of Innovative Medicines Canada, gives insights into the adoption of innovative technologies, domestic supply chain for pharmaceuticals, and excluding medicines as retaliatory measures for tariffs.

Paul Levesque, President and CEO of Theratechnologies Inc., gives insights into innovation in biopharma, the effects of tariffs on supply chain and pharma manufacturing, and cross-border business development.

Mark Nawacki, President and CEO of Searchlight Pharma, gives insights into starting a specialty pharma business, therapeutics for women’s health and migraine relief, and the shift to more personalized medicines in healthcare.

Lisa Mullett, Senior Vice-President of Sumitomo Pharma America, gives insights into the importance of diversity in companies and patient trials, stepping out of your comfort zone to further your career, and accelerating development with AI.

Tom Slowe, CEO of Breadcrumb Analytics, gives insights into using AI to sort and sift through statistics, the importance of context with data, and why AI should only be supplementary to human work.

Kenneth Custer, President and General Manager of Eli Lilly Canada, gives insights into his background in neuroscience, innovation in healthcare, and progress in therapeutics for obesity and Alzheimer’s.

Jonathan Soong, General Manager of Amicus Therapeutics, gives insights into being at the forefront of rare disease innovations, patient support programs, and the importance of real world evidence for rare diseases.

Rodrigo Reis, General Manager of UCB Pharma Canada, gives insights into fostering innovation in pharma, collaborating with UHN to expedite diagnoses, and entering the rare disease space with new innovative therapeutics.

John McKendry, President and CEO of KYE, gives insights into the importance of operating within regulations, leadership in pharma, and new treatment and delivery options for ADHD.